Journey Medical Corp expected to post a loss of 2 cents a share - Earnings Preview

Journey Medical

10/08/2026 21:56

Journey Medical Corp DERM.OQ DERM.O is expected to  show a rise in quarterly revenue when it reports  results on August 12 for the period ending June 30 2026
The Scottsdale Arizona-based  company is expected to report a 22.4% increase in revenue to $18.367 million from $15.01 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Journey Medical Corp is for a loss of 2 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Journey Medical Corp is $13.00, about 102.2% above its last closing price of $6.43
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.08
-0.08
-0.08
Met
-3.2
Dec. 31 2026
-0.07
-0.06
-0.05
Beat
20
Sep. 30 2025
-0.04
-0.05
-0.09
Missed
-89.5​
Jun. 30 2025
-0.10
-0.10
-0.16
Missed
-52.4
​​Mar. 31 2025
-0.23
-0.24
-0.18
Beat
24.2
Dec. 31 2024
-0.35
-0.15
Beat
57.4​
Sep. 30 2024
-0.14
-0.15
-0.17
Missed
-15.3
Jun. 30 2024
-0.14
-0.14
-0.17
Missed
-18.6
This summary was machine generated August 10 at 20:56 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)